摘要
目的:探讨恒古骨伤愈合剂对于发作、缓解期膝骨关节炎患者疗效的改善情况并对其潜在干预机制进行系统挖掘,为提高恒古骨伤愈合剂的临床应用价值、指导其临床合理用药提供一定参考。方法:通过恒古骨伤愈合剂治疗膝骨关节炎的真实世界研究,获得数据资料并录入“恒古骨伤愈合剂治疗膝骨关节炎病例注册登记系统”,在系统中选取2020年5月1日至2021年12月31日来自北京中医药大学第三附属医院、北京协和医院、中国中医科学院望京医院和湖南航天医院等20家医疗机构骨伤科门诊或住院的105例发作、缓解期膝骨关节炎患者,包括60例联用恒古骨伤愈合剂和关节注射治疗的患者,及45例单用关节注射治疗的患者。观察和对比2组患者的西安大略麦克马斯特大学骨关节炎指数(WOMAC)评分、视觉模拟(VAS)疼痛评分、中医单项疼痛症状种类(冷痛、热痛、刺痛、隐痛、酸痛)和其他中医症状,并进行统计学分析。为进一步阐释恒古骨伤愈合剂联用关节注射治疗发作、缓解期膝骨关节炎的潜在分子机制,本研究利用“骨伤交叉数据库(BX-Data,http://bone-xtrans.com/database)”,收集膝骨关节炎疾病基因集、恒古骨伤愈合剂组方中药材、化学成分、物质基础、候选靶标、玻璃酸钠候选靶标数据进行筛选,构建“疾病靶标”的互作网络。结果:入组的105例膝骨关节炎患者中,发作期患者占15.24%(16/105),缓解期患者占84.76%(89/105),无康复期患者。女性72例(68.57%),多于男性33例(31.43%),105例患者中观察组60例,对照组45例;观察组VAS评分5分患者20例、6分患者19例,共占观察组65.00%;对治疗前后组间VAS评分的比较结果表明,治疗后4周两组评分分别为(4.42±1.01)分、(5.00±1.02)分,治疗后8周分别为(3.12±1.04)分、(3.56±1.08)分,均低于治疗前(6.23±1.28)分、(6.02±1.22)分(P<0.05);对两组疼痛性质的比较结果表明,观
Objective:To investigate the improvement of the efficacy of Osteoking in patients with knee osteoarthritis in the onset and remission stage and to systematically explore its potential intervention mechanism,so as to provide a certain reference for improving the clinical application value of Osteoking and guiding its clinical rational drug use.Method:Through the real-world study of the treatment of knee osteoarthritis with Osteoking,the data was obtained and entered into the"Osteoking for the treatment of knee osteoarthritis case registration system",and 105 patients with episodic and remission knee osteoarthritis from the outpatient or inpatient orthopedic department of 20 medical institutions,including the Third Affiliated Hospital of Beijing University of Chinese Medicine,Peking Union Medical College Hospital,Wangjing Hospital of the Chinese Academy of Chinese Medical Sciences and Hunan Aerospace Hospital,from May 1,2020 to December 31,2021,were selected in the system.It included 60 patients treated with Osteoking and joint injection,and 45 patients treated with joint injection alone.The WOMAC osteoarthritis index score,visual analogue(VAS)pain score,individual types of pain symptoms(cold pain,hot pain,tingling,dull pain,soreness)and other TCM symptoms were observed and compared between the two groups,and statistically analyzed.In order to further elucidate the potential molecular mechanism of Osteoking combined with joint injection in the treatment of knee osteoarthritis in the treatment of onset and remission,this study used the"Bone Injury Cross Database(http://bone-xtrans.com/database,BX-Data)"to collect the gene set of knee osteoarthritis disease,the traditional Chinese medicinal materials,chemical composition,material base,candidate target,candidate target,sodium hyaluronate candidate target data for screening,and constructed an interaction network of"disease target".Results:Among the 105 patients with knee osteoarthritis enrolled,15.24%(16/105)were in the episodic period,84.76%(89/105)were in remission,a
作者
全锐
周峻
贾雁
颜炎
高帅
梁志
李瑞涵
李述文
张彦琼
翁习生
林娜
宓保宏
陈卫衡
QUAN Rui;ZHOU Jun;JIA Yan;YAN Yan;GAO Shuai;LIANG Zhi;LI Ruihan;LI Shuwen;ZHANG Yanqiong;WENG Xisheng;LIN Na;MI Baohong;CHEN Weiheng(The Third Affiliated Hospital of Beijing University of Chinese Medicine,Beijing 100029,China;Engineering Research Center of Chinese Orthopaedic and Sports Rehabilitation Artificial Intelligent,Ministry of Education,Beijing 100029,China;Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China;Peking Union Medical College,Beijing 100730,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2023年第24期72-79,共8页
Chinese Journal of Experimental Traditional Medical Formulae
基金
首都卫生发展科研重点攻关专项(首发2022-1-7032)。
